Gilead Science's remdesivir manufacturing projections 2020

Cumulative amount of remdesivir treatment courses projected to be manufactured by Gilead Sciences during 2020

CharacteristicCumulative treatment courses in thousands
December 2,000
July 288
June 190
April 30
January 5
Created with Highcharts 7.2.2Cumulative treatment courses in thousands5530301901902882882,0002,000JanuaryAprilJuneJulyDecember
05001,0001,5002,0002,500
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

July 2020

Region

United States

Survey time period

as of July 2020

Supplementary notes

Original manufacturing projections from January to May based on 11-vial treatment course. Projections through end of June based on average 7.78 vials per treatment course. Year-end projection based on average 6.25 vials per treatment course.
Figures reflect the cumulative amount of drug that Gilead expects to produce and are inclusive of supply allocated for clinical trials, compassionate use and expanded access programs, and any potential regulatory authorizations or approvals.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$1,299 USD
per month, billed annually 1
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Leading companies trust Statista:
paypal google adobe pg samsung telekom

Related reports: Available to download in PDF or PPTX format

All datain one format
All data
in one format
Coronavirus: the pharma and medtech response

Everything on "Coronavirus: the pharma and medtech response" in one document: edited and divided into chapters, including detailed references.

I think of Statista as Google for researchers. Statista provides you with the information you search for right away.
Dr. Horst Stipp

Dr. Horst Stipp
EVP, Research & Innovation, Advertising Research Foundation

Statistics on " Coronavirus: the pharma and medtech response "

Other statistics that may interest you Coronavirus: the pharma and medtech response

Pharma - before the pandemic

6

Treatments and vaccines

8

Focus: BioNTech and Moderna

7

Opinions on COVID-19 vaccines

6

Business impact

4

Medtech - before the pandemic

5

Ventilators and testing

7

Further related statistics

19

Discover Statista

Need help with using Statista for your research? Tutorials and first steps

Further Content: You might find this interesting as well

Do you have any questions about our business solutions?

We provide you with detailed information about our Professional Account.

Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$1,299 USD
per month, billed annually 1
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Learn more about how Statista can support your business.